MGA’s analysis of the competition as new adalimumab biosimilars enter market.
“The launches this month are “more of an inflection point in the market compared to what we saw in January when Amjevita came to market,” said Alex Brill.
Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings?
MGA’s Alex Brill was interviewed by Mari Serebvrov for a new piece in BioWorld to discuss the latest with the adalimumab market as new competition is expected as early as July 1.
The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.